Apolipoprotein E genotype is not linked to locally recurrent hormone-refractory prostate cancer
Mechanisms of prostate cancer recurrence during androgen deprivation are poorly understood. Recently, the putative role of apolipoprotein E varepsilon 4 allele in the aetiology of prostate cancer was raised. To investigate the hypothesis that varepsilon 4 allele of apolipoprotein E gene predisposes...
Gespeichert in:
| Veröffentlicht in: | Prostate cancer and prostatic diseases 2000-08, Vol.3 (2), p.107-109 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 109 |
|---|---|
| container_issue | 2 |
| container_start_page | 107 |
| container_title | Prostate cancer and prostatic diseases |
| container_volume | 3 |
| creator | Haapala, K Lehtimäki, T Ilveskoski, E Koivisto, P A Haapala, K |
| description | Mechanisms of prostate cancer recurrence during androgen deprivation are poorly understood. Recently, the putative role of apolipoprotein E varepsilon 4 allele in the aetiology of prostate cancer was raised. To investigate the hypothesis that varepsilon 4 allele of apolipoprotein E gene predisposes to prostate cancer and is involved in the relapse of hormonal therapy response, 38 hormone-refractory locally recurrent carcinoma samples from 38 prostate cancer patients were screened for apolipoprotein E genotype. The frequency distribution of apolipoprotein E genotypes among tumours did not differ significantly from that among controls. The allele frequency of varepsilon 4 was 19.7% and 19.3% in tumours and controls, respectively. The results suggest that clinical progression of prostate cancer during androgen withdrawal therapy is not associated with apolipoprotein E genotype. Prostate Cancer and Prostatic Diseases (2000) 3, 107-109 |
| doi_str_mv | 10.1038/sj.pcan.4500405 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1859387532</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1859387532</sourcerecordid><originalsourceid>FETCH-LOGICAL-c350t-bb7d285cbeca2e41dbc153a4c5120bb66a2586b7c784704f8b9364f2e958dff23</originalsourceid><addsrcrecordid>eNp1kTlv3DAQhYkgQXwkdbqAiBs3Wg8vkSoNwxdgwE1SEyQ1SrTRijJJFfvvzYUXMBAg1bzimzfHI-Qbgw0DYa7ydrMEN2-kApCgPpBTJnXbqBbMx6pFqxptFD8hZzlvAaBjHXwmJ4zLTjPQp8ReL3Eal7ikWHCc6S39jXMs-wXpmGlVdBrnv9jTEukUg5umPU0Y1pRwLvRPTLs4Y5NwSC6UmPa0GuXiCtK6VsD0hXwa3JTx67Gek193tz9vHpqn5_vHm-unJggFpfFe99yo4DE4jpL1PjAlnAyKcfC-bR1XpvU6aCM1yMH4TrRy4Ngp0w8DF-fk8s23zn9ZMRe7G3PAaXIzxjVbZlQnjFbigF78g27jmua6neWtrISsr63Uj_9SvAMlNJgKXb1BoV6d6xfsksadS3vLwB4CsnlrDwHZY0C14_vRdvU77N_5YyLiFbhHjWg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>229053708</pqid></control><display><type>article</type><title>Apolipoprotein E genotype is not linked to locally recurrent hormone-refractory prostate cancer</title><source>Springer Nature - Complete Springer Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Haapala, K ; Lehtimäki, T ; Ilveskoski, E ; Koivisto, P A ; Haapala, K</creator><creatorcontrib>Haapala, K ; Lehtimäki, T ; Ilveskoski, E ; Koivisto, P A ; Haapala, K</creatorcontrib><description>Mechanisms of prostate cancer recurrence during androgen deprivation are poorly understood. Recently, the putative role of apolipoprotein E varepsilon 4 allele in the aetiology of prostate cancer was raised. To investigate the hypothesis that varepsilon 4 allele of apolipoprotein E gene predisposes to prostate cancer and is involved in the relapse of hormonal therapy response, 38 hormone-refractory locally recurrent carcinoma samples from 38 prostate cancer patients were screened for apolipoprotein E genotype. The frequency distribution of apolipoprotein E genotypes among tumours did not differ significantly from that among controls. The allele frequency of varepsilon 4 was 19.7% and 19.3% in tumours and controls, respectively. The results suggest that clinical progression of prostate cancer during androgen withdrawal therapy is not associated with apolipoprotein E genotype. Prostate Cancer and Prostatic Diseases (2000) 3, 107-109</description><identifier>ISSN: 1365-7852</identifier><identifier>EISSN: 1476-5608</identifier><identifier>DOI: 10.1038/sj.pcan.4500405</identifier><identifier>PMID: 12497107</identifier><language>eng</language><publisher>England: Nature Publishing Group</publisher><subject>Alleles ; Androgens ; Apolipoprotein E ; Apolipoproteins ; Deprivation ; E protein ; Frequency distribution ; Gene frequency ; Genotype & phenotype ; Genotypes ; Prostate cancer ; Tumors</subject><ispartof>Prostate cancer and prostatic diseases, 2000-08, Vol.3 (2), p.107-109</ispartof><rights>Copyright Nature Publishing Group Aug 2000</rights><rights>Macmillan Publishers Limited 2000.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c350t-bb7d285cbeca2e41dbc153a4c5120bb66a2586b7c784704f8b9364f2e958dff23</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12497107$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Haapala, K</creatorcontrib><creatorcontrib>Lehtimäki, T</creatorcontrib><creatorcontrib>Ilveskoski, E</creatorcontrib><creatorcontrib>Koivisto, P A</creatorcontrib><creatorcontrib>Haapala, K</creatorcontrib><title>Apolipoprotein E genotype is not linked to locally recurrent hormone-refractory prostate cancer</title><title>Prostate cancer and prostatic diseases</title><addtitle>Prostate Cancer Prostatic Dis</addtitle><description>Mechanisms of prostate cancer recurrence during androgen deprivation are poorly understood. Recently, the putative role of apolipoprotein E varepsilon 4 allele in the aetiology of prostate cancer was raised. To investigate the hypothesis that varepsilon 4 allele of apolipoprotein E gene predisposes to prostate cancer and is involved in the relapse of hormonal therapy response, 38 hormone-refractory locally recurrent carcinoma samples from 38 prostate cancer patients were screened for apolipoprotein E genotype. The frequency distribution of apolipoprotein E genotypes among tumours did not differ significantly from that among controls. The allele frequency of varepsilon 4 was 19.7% and 19.3% in tumours and controls, respectively. The results suggest that clinical progression of prostate cancer during androgen withdrawal therapy is not associated with apolipoprotein E genotype. Prostate Cancer and Prostatic Diseases (2000) 3, 107-109</description><subject>Alleles</subject><subject>Androgens</subject><subject>Apolipoprotein E</subject><subject>Apolipoproteins</subject><subject>Deprivation</subject><subject>E protein</subject><subject>Frequency distribution</subject><subject>Gene frequency</subject><subject>Genotype & phenotype</subject><subject>Genotypes</subject><subject>Prostate cancer</subject><subject>Tumors</subject><issn>1365-7852</issn><issn>1476-5608</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNp1kTlv3DAQhYkgQXwkdbqAiBs3Wg8vkSoNwxdgwE1SEyQ1SrTRijJJFfvvzYUXMBAg1bzimzfHI-Qbgw0DYa7ydrMEN2-kApCgPpBTJnXbqBbMx6pFqxptFD8hZzlvAaBjHXwmJ4zLTjPQp8ReL3Eal7ikWHCc6S39jXMs-wXpmGlVdBrnv9jTEukUg5umPU0Y1pRwLvRPTLs4Y5NwSC6UmPa0GuXiCtK6VsD0hXwa3JTx67Gek193tz9vHpqn5_vHm-unJggFpfFe99yo4DE4jpL1PjAlnAyKcfC-bR1XpvU6aCM1yMH4TrRy4Ngp0w8DF-fk8s23zn9ZMRe7G3PAaXIzxjVbZlQnjFbigF78g27jmua6neWtrISsr63Uj_9SvAMlNJgKXb1BoV6d6xfsksadS3vLwB4CsnlrDwHZY0C14_vRdvU77N_5YyLiFbhHjWg</recordid><startdate>200008</startdate><enddate>200008</enddate><creator>Haapala, K</creator><creator>Lehtimäki, T</creator><creator>Ilveskoski, E</creator><creator>Koivisto, P A</creator><creator>Haapala, K</creator><general>Nature Publishing Group</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>M7Z</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>200008</creationdate><title>Apolipoprotein E genotype is not linked to locally recurrent hormone-refractory prostate cancer</title><author>Haapala, K ; Lehtimäki, T ; Ilveskoski, E ; Koivisto, P A ; Haapala, K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c350t-bb7d285cbeca2e41dbc153a4c5120bb66a2586b7c784704f8b9364f2e958dff23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Alleles</topic><topic>Androgens</topic><topic>Apolipoprotein E</topic><topic>Apolipoproteins</topic><topic>Deprivation</topic><topic>E protein</topic><topic>Frequency distribution</topic><topic>Gene frequency</topic><topic>Genotype & phenotype</topic><topic>Genotypes</topic><topic>Prostate cancer</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Haapala, K</creatorcontrib><creatorcontrib>Lehtimäki, T</creatorcontrib><creatorcontrib>Ilveskoski, E</creatorcontrib><creatorcontrib>Koivisto, P A</creatorcontrib><creatorcontrib>Haapala, K</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Biochemistry Abstracts 1</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Prostate cancer and prostatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Haapala, K</au><au>Lehtimäki, T</au><au>Ilveskoski, E</au><au>Koivisto, P A</au><au>Haapala, K</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Apolipoprotein E genotype is not linked to locally recurrent hormone-refractory prostate cancer</atitle><jtitle>Prostate cancer and prostatic diseases</jtitle><addtitle>Prostate Cancer Prostatic Dis</addtitle><date>2000-08</date><risdate>2000</risdate><volume>3</volume><issue>2</issue><spage>107</spage><epage>109</epage><pages>107-109</pages><issn>1365-7852</issn><eissn>1476-5608</eissn><abstract>Mechanisms of prostate cancer recurrence during androgen deprivation are poorly understood. Recently, the putative role of apolipoprotein E varepsilon 4 allele in the aetiology of prostate cancer was raised. To investigate the hypothesis that varepsilon 4 allele of apolipoprotein E gene predisposes to prostate cancer and is involved in the relapse of hormonal therapy response, 38 hormone-refractory locally recurrent carcinoma samples from 38 prostate cancer patients were screened for apolipoprotein E genotype. The frequency distribution of apolipoprotein E genotypes among tumours did not differ significantly from that among controls. The allele frequency of varepsilon 4 was 19.7% and 19.3% in tumours and controls, respectively. The results suggest that clinical progression of prostate cancer during androgen withdrawal therapy is not associated with apolipoprotein E genotype. Prostate Cancer and Prostatic Diseases (2000) 3, 107-109</abstract><cop>England</cop><pub>Nature Publishing Group</pub><pmid>12497107</pmid><doi>10.1038/sj.pcan.4500405</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1365-7852 |
| ispartof | Prostate cancer and prostatic diseases, 2000-08, Vol.3 (2), p.107-109 |
| issn | 1365-7852 1476-5608 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1859387532 |
| source | Springer Nature - Complete Springer Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Alleles Androgens Apolipoprotein E Apolipoproteins Deprivation E protein Frequency distribution Gene frequency Genotype & phenotype Genotypes Prostate cancer Tumors |
| title | Apolipoprotein E genotype is not linked to locally recurrent hormone-refractory prostate cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T20%3A25%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Apolipoprotein%20E%20genotype%20is%20not%20linked%20to%20locally%20recurrent%20hormone-refractory%20prostate%20cancer&rft.jtitle=Prostate%20cancer%20and%20prostatic%20diseases&rft.au=Haapala,%20K&rft.date=2000-08&rft.volume=3&rft.issue=2&rft.spage=107&rft.epage=109&rft.pages=107-109&rft.issn=1365-7852&rft.eissn=1476-5608&rft_id=info:doi/10.1038/sj.pcan.4500405&rft_dat=%3Cproquest_cross%3E1859387532%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=229053708&rft_id=info:pmid/12497107&rfr_iscdi=true |